Article Data

  • Views 448
  • Dowloads 104

Original Research

Open Access

Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer

  • Y. Li1,*,
  • X. Wang1
  • J. Li1
  • W. Ding1

1Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People’s Republic of China

DOI: 10.12892/ejgo2556.2015 Vol.36,Issue 1,February 2015 pp.54-58

Published: 10 February 2015

*Corresponding Author(s): Y. Li E-mail: liyf@sysucc.org.cn

Abstract

Objectives: To investigate the efficacy and toxicities of combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy (NACT) in locally advanced cervical cancer. Materials and Methods: The authors retrospectively reviewed the clinical records of patients with cervical cancer who received NACT with liposomal paclitaxel and cisplatin at Sun Yat-sen University Cancer Center from April 1, 2008 to December 31, 2012. Liposomal paclitaxel and cisplatin was administrated intravenously at a dose of 175 mg/m2 and 75 mg/m2, respectively. Results: The total response rate was 86.1% (62/72) including a complete response and partial response rate of 27.8 % (20/72) and 58.3% (42/72), respectively. Stable disease was observed in 12.5 % (9/72) of patients and progressive disease in 1.4 % (1/72). Hematological toxicities were the major dose-limiting toxicities. Grade 3/4 neutropenia and anemia developed in 18.1% (13/72) and 6.9% (5/72) of patients, respectively. Peripheral neuropathy occurred in 6.9% (5/72) of patients (all grade 1). Conclusion: the study findings support further evaluation of liposomal paclitaxel with cisplatin as an additional chemotherapy regimen which may be efficacious and tolerable in the NACT of cervical cancer.

Keywords

Cervical cancer; Neoadjuvant chemotherapy; Liposomal paclitaxel; Locally advanced.

Cite and Share

Y. Li,X. Wang,J. Li,W. Ding. Combination therapy of liposomal paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. European Journal of Gynaecological Oncology. 2015. 36(1);54-58.

References

[1] http://www.cancer.org/cancer/news/expertvoices/category/cervicalcancer.aspx. Accessed on 05/08/2013.

[2] Kokawa K., Takekida S-, Kamiura S., Kita M., Enomoto T., Kawaguchi R., et al.: “The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan”. Eur. J. Gynaecol. Oncol., 2010, 31, 37.

[3] Eifel P.J.: “Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer”. Nat. Clin. Pract. Oncol., 2006, 3, 248.

[4] Loizzi V., Cormio G., Vicino M., Selvaggi L.: “Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer”. Gynecol. Obstet. Invest., 2008, 65, 96.

[5] Gonzalez-Martin A., Gonzalez-Cortijo L., Carballo N., Garcia J.F., Lapuente F., Rojo A., et al.: “The current role of neoadjuvant chemotherapy in the management of cervical carcinoma”. Gynecol. Oncol., 2008, 110, S36.

[6] Weiss R.B., Donehower R.C., Wiernik P.H., Ohnuma T., Gralla R.J., Trump D.L., et al.: “Hypersensitivity reactions from taxol”. J. Clin. Oncol., 1990, 8, 1263.

[7] Schiller J.H., Storer B., Tutsch K., Arzoomanian R., Alberti D., Feierabend C., et al.: “Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer”. J. Clin. Oncol., 1994, 12, 241.

[8] Chang A.Y., Boros L., Garrow G., Asbury R.: “Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease”. Semin. Oncol., 1995, 22, 124.

[9] Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., et al.: “Activity of paclitaxel liposome formulations against human ovarian tumor xenografts”. Int. J. Cancer, 1997, 71, 103.

[10] Cabanes A., Briggs K.E., Gokhale P.C., Treat J.A., Rahman A.: “Comparative in vivo studies with paclitaxel and liposome-encapsulated paclitaxel”. Int. J. Oncol., 1998, 12, 1035.

[11] Guo W., Johnson J.L., Khan S., Ahmad A., Ahmad I.: “Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetics study”. Anal. Biochem., 2005, 336, 213.

[12] Yan F., Li L., Deng Z., Jin Q., Zheng H.: “Paclitaxel-liposome loaded microbubbles for ultrasound-triggered drug delivery in vitro and in vivo”. J. Acoust. Soc. Am., 2012, 166, 246.

[13] Chen Q., Zhang Q.Z., Liu J., Li L.Q., Zhao W.H., Wang Y.J., et al.: “Multi-center prospective randomized trial on paclitaxel liposome and traditional taxol in the treatment of breast cancer and non-smallcell lung cancer”. Zhonghua Zhong Liu Za Zhi, 2003, 25, 190.

[14] Wu F., Chen S.C., Lu Z.H., Xiong J.P.: “Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer”. Zhonghua Zhong Liu Za Zhi, 2010, 32, 234.

[15] Yang X., Zhang H., Nong J., Wang J., Li X., Zhang Q., et al.: “A randomized trial of liposomal paclitaxel plus cisplatin as first-line therapy for advanced non-small cell lung cancer”. Zhongguo Fei Ai Za Zhi, 2012, 15, 208.

[16] Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al.: “New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada”. J. Natl. Cancer Inst., 2000, 92, 205.

[17] The NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4 (Active as of 06/14/2010). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed on 03/08/2013.

[18] Cockcroft D.W., Gault M.H.: “Prediction of creatinine clearance from serum creatinine”. Nephron, 1976, 16, 31.

[19] Li Y., Finkel K.W., Hu W., Fu S., Liu J., Coleman R., et al.: “Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction”. Gynecol. Oncol., 2007, 106, 375.

[20] Zhang R., Li B., Bai P., Li H.J., Li S.M., Wu L.Y., et al.: “Neoadjuvant chemotherapy with paclitaxel and cisplantin or carboplatin for patients with locally advanced uterine cervical cancer”. Zhonghua Zhong Liu Za Zhi, 2011, 33, 616.

[21] Moioli M., Papadia A., Mammoliti S., Pacella E., Menoni S., Menada M.V., et al.: “Chemotherapy with cisplatin and paclitaxel in locally advanced cervical cancer: has this regimen still a role as neoadjuvant setting?” Minerva Ginecol., 2012, 64, 95.

[22] Park D.C., Kim J.H., Lew Y.O., Kim D.H., Namkoong S.E.: “Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer”. Gynecol. Oncol., 2004, 92, 59.

[23] Zeng S.Y., Li L., Zhong M.L., Jiang W., Wu Y.Y., Liu Y.: “A randomized controlled trial of two chemotherapy regimens (paclitaxel liposome combined with platinum and paclitaxel combined with platinum) in concurrent chemoradiotherapy for cervical carcinoma”. Zhonghua Zhong Liu Za Zhi, 2011, 33, 517.

[24] Gadducci A., Teti G., Barsotti C., Tana R., Fanucchi A., Orlandini C., et al.: “Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin- based neoadjuvant chemotherapy followed by radical hysterectomy”. Anticancer Res., 2010, 30, 201.

[25] Candelaria M., Chanona-Vilchis J., Cetina L., Flores-Estrada D., Lopez-Graniel C., Gonzalez-Enciso A., et al.: “Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma. Int. Semin. Surg. Oncol., 2006, 3, 3.

[26] Sharma A., Mayhew E., Straubinger R.M.: “Antitumor effect of taxolcontaining liposomes in a taxol-resistant murine tumor model”. Cancer Res., 1993, 53, 5877.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top